English

Momenta Pharmaceuticals, Inc.

EDGAR

MNTA Quarterly report (10-Q) · filed 2020-08-10

180 filing records in this dataset, filed from 2004-08-16 to 2020-08-10. Reported financial figures are available; chart coverage varies by period.

Inspect reported changes Compare with another company Historical disclosures Search filings Segments

Watchlist

Latest quarter

Revenue

6.61 million USD

2020 Q2 · USD

Exact inputs and evidence

Revenue: 6610000 USD Source

Operating margin

-868.05%

2020 Q2 · %

Exact inputs and evidence

Operating Income: -57378000 USD Source
Revenue: 6610000 USD Source

Operating cash flow

-41.1 million USD

2020 Q2 · USD

Exact inputs and evidence

Operating Cash Flow: -105692000 USD Source
Operating Cash Flow: -64615000 USD Source

Free cash flow

-42 million USD

2020 Q2 · USD

Exact inputs and evidence

Operating Cash Flow: -105692000 USD Source
Operating Cash Flow: -64615000 USD Source
Capital Expenditure: 1734000 USD Source
Capital Expenditure: 857000 USD Source

Cash and cash equivalents: 191 million USD 2020-06-30 Source
Exact value

191124000 USD
Long-term debt including current maturities: Not available
Shares outstanding: 119 million shares 2020-06-30 Source
Exact value

118595000 shares

Reported share-count change

20.18% · 19.9 million shares

Year-over-year change in reported shares. Splits, issuance and buybacks can affect this figure; it does not isolate employee compensation or economic dilution.

Exact inputs and evidence

98683000 shares · 2019-06-30· Source
118595000 shares · 2020-06-30· Source

Trailing twelve months

The four most recent complete quarters added together. This gives a full-year view that includes the latest quarterly results.

Net income

218 million USD

2010-10-01 – 2011-09-30

Exact inputs and evidence

Net income: 37290000 USD · 2010-01-01 – 2010-12-31 Source
Net income: 1032000 USD · 2010-01-01 – 2010-09-30 Source
Net income: 57006000 USD · 2011-01-01 – 2011-03-31 Source
Net income: 64265000 USD · 2011-04-01 – 2011-06-30 Source
Net income: 60338000 USD · 2011-07-01 – 2011-09-30 Source

Includes later revisions to earlier periods. Annual charts exclude incomplete years.

Latest filing recorded: 2020-08-10.

Financial data available through: 2019-12-31.

Coverage by financial measure

Revenue: 11 of 11 periods available· newest 2019-12-31
Operating income: 11 of 11 periods available· newest 2019-12-31
Net income: 2 of 11 periods available· newest 2010-12-31
Operating cash flow: 11 of 11 periods available· newest 2019-12-31
Capital expenditure: 11 of 11 periods available· newest 2019-12-31
Total assets: 10 of 11 periods available· newest 2019-12-31
Total liabilities: 10 of 11 periods available· newest 2019-12-31
Current assets: 10 of 11 periods available· newest 2019-12-31
Current liabilities: 10 of 11 periods available· newest 2019-12-31
Cash and cash equivalents: 11 of 11 periods available· newest 2019-12-31
long term debt: No compatible figures in this window
Shares outstanding: 9 of 11 periods available· newest 2019-12-31

Coverage describes values retained in this snapshot. Missing values are not zero; loading limits are reported separately.

What changed year over year

Latest complete year compared with the corresponding period one year earlier. These are measured changes; they do not establish their business causes.

Revenue
-68.4%

Prior period

USD 75.59 million

2018-01-01 – 2018-12-31
Current period

USD 23.87 million

2019-01-01 – 2019-12-31

Exact inputs and evidence

23868000 − 75589000 = -51721000 USD

75589000 USD · 2018-01-01 – 2018-12-31
Inspect prior input Prior source
23868000 USD · 2019-01-01 – 2019-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Revenue · Momenta Pharmaceuticals, Inc. · 2019-12-31 Momenta Pharmaceuticals, Inc. (edgar:1235010) Year-over-year change in Revenue: -51721000 USD Concept: fundies:Revenue Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-02T09:32:59Z Snapshot: 2e167c544acd282b1ed83fd55a50ba564bc60fa7bc814e8250bdebe50baf9663 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1235010?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:Revenue: 23868000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1235010/000123501020000003/mnta1231201910k.htm#2225617 Filing: 000123501020000003 Input fundies:Revenue: 75589000 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1235010/000123501020000003/mnta1231201910k.htm#2275305 Filing: 000123501020000003
The citation records this snapshot. The page link may show a newer release later.
Operating cash flow
−USD 49.21 million

Prior period

−USD 155.59 million

2018-01-01 – 2018-12-31
Current period

−USD 204.8 million

2019-01-01 – 2019-12-31

Exact inputs and evidence

-204802000 − -155590000 = -49212000 USD

-155590000 USD · 2018-01-01 – 2018-12-31
Inspect prior input Prior source
-204802000 USD · 2019-01-01 – 2019-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Operating cash flow · Momenta Pharmaceuticals, Inc. · 2019-12-31 Momenta Pharmaceuticals, Inc. (edgar:1235010) Year-over-year change in Operating cash flow: -49212000 USD Concept: fundies:OperatingCashFlow Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-02T09:32:59Z Snapshot: 2e167c544acd282b1ed83fd55a50ba564bc60fa7bc814e8250bdebe50baf9663 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1235010?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:OperatingCashFlow: -204802000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1235010/000123501020000003/mnta1231201910k.htm#1496086 Filing: 000123501020000003 Input fundies:OperatingCashFlow: -155590000 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1235010/000123501020000003/mnta1231201910k.htm#1497161 Filing: 000123501020000003
The citation records this snapshot. The page link may show a newer release later.
Capital expenditure
-80.3%

Prior period

USD 9.02 million

2018-01-01 – 2018-12-31
Current period

USD 1.78 million

2019-01-01 – 2019-12-31

Exact inputs and evidence

1776000 − 9019000 = -7243000 USD

9019000 USD · 2018-01-01 – 2018-12-31
Inspect prior input Prior source
1776000 USD · 2019-01-01 – 2019-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Capital expenditure · Momenta Pharmaceuticals, Inc. · 2019-12-31 Momenta Pharmaceuticals, Inc. (edgar:1235010) Year-over-year change in Capital expenditure: -7243000 USD Concept: fundies:CapitalExpenditure Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-02T09:32:59Z Snapshot: 2e167c544acd282b1ed83fd55a50ba564bc60fa7bc814e8250bdebe50baf9663 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1235010?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:CapitalExpenditure: 1776000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1235010/000123501020000003/mnta1231201910k.htm#1502339 Filing: 000123501020000003 Input fundies:CapitalExpenditure: 9019000 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1235010/000123501020000003/mnta1231201910k.htm#1503235 Filing: 000123501020000003
The citation records this snapshot. The page link may show a newer release later.

Comparable inputs unavailable for: Net income.

Where revenue goes

How a period’s revenue divides into costs and what remains as profit. Items marked Derived are calculated by subtraction from reported figures.

2019 2019-01-01 – 2019-12-31

Revenue USD 23.87 million 100% of revenue
Operating costs Derived USD 321.96 million 1,349% of revenue
Operating income −USD 298.09 million −1,249% of revenue
Tax, interest and other Derived Unavailable An input is unavailable.
Net income Unavailable An input is unavailable.

Cash

Operating cash flow −USD 204.8 million −858% of revenue
Capital expenditure USD 1.78 million 7.4% of revenue
Free cash flow Derived −USD 206.58 million −866% of revenue

Share of revenue by period

Net income
Tax, interest and other
Operating costs

2010 Net income was higher than operating income, so the split is not drawn.
2011 Not shown: operating income or net income is not reported.
2012 Not shown: operating income or net income is not reported.
2013 Not shown: operating income or net income is not reported.
2014 Not shown: operating income or net income is not reported.
2015 Not shown: operating income or net income is not reported.
2016 Not shown: operating income or net income is not reported.
2017 Not shown: operating income or net income is not reported.
2018 Not shown: operating income or net income is not reported.
2019 Not shown: operating income or net income is not reported.

Values and sources

Revenue breakdown by annual reporting period
Period	Revenue	Operating costs	Operating income	Tax, interest and other	Net income	Free cash flow	Source
2010 2010-01-01 – 2010-12-31	116772000	80307000 Derived	36465000	-825000 Derived	37290000	-2728000 Derived	Source 2010-01-01 – 2010-12-31: 116772000 USD Inspect Revenue Open source 2010-01-01 – 2010-12-31: 36465000 USD Inspect Operating Income Open source 2010-01-01 – 2010-12-31: 37290000 USD Inspect Net Income Open source 2010-01-01 – 2010-12-31: -1057000 USD Inspect Operating Cash Flow Open source 2010-01-01 – 2010-12-31: 1671000 USD Inspect Capital Expenditure Open source
2011 2011-01-01 – 2011-12-31	283068000	103367000 Derived	179701000	Unavailable	Unavailable	205026000 Derived	Source 2011-01-01 – 2011-12-31: 283068000 USD Inspect Revenue Open source 2011-01-01 – 2011-12-31: 179701000 USD Inspect Operating Income Open source 2011-01-01 – 2011-12-31: 213725000 USD Inspect Operating Cash Flow Open source 2011-01-01 – 2011-12-31: 8699000 USD Inspect Capital Expenditure Open source
2012 2012-01-01 – 2012-12-31	63921000	124027000 Derived	-60106000	Unavailable	Unavailable	-6492000 Derived	Source 2012-01-01 – 2012-12-31: 63921000 USD Inspect Revenue Open source 2012-01-01 – 2012-12-31: -60106000 USD Inspect Operating Income Open source 2012-01-01 – 2012-12-31: 8999000 USD Inspect Operating Cash Flow Open source 2012-01-01 – 2012-12-31: 15491000 USD Inspect Capital Expenditure Open source
2013 2013-01-01 – 2013-12-31	35465000	145056000 Derived	-109591000	Unavailable	Unavailable	-96282000 Derived	Source 2013-01-01 – 2013-12-31: 35465000 USD Inspect Revenue Open source 2013-01-01 – 2013-12-31: -109591000 USD Inspect Operating Income Open source 2013-01-01 – 2013-12-31: -86832000 USD Inspect Operating Cash Flow Open source 2013-01-01 – 2013-12-31: 9450000 USD Inspect Capital Expenditure Open source
2014 2014-01-01 – 2014-12-31	52250000	151646000 Derived	-99396000	Unavailable	Unavailable	-73528000 Derived	Source 2014-01-01 – 2014-12-31: 52250000 USD Inspect Revenue Open source 2014-01-01 – 2014-12-31: -99396000 USD Inspect Operating Income Open source 2014-01-01 – 2014-12-31: -65168000 USD Inspect Operating Cash Flow Open source 2014-01-01 – 2014-12-31: 8360000 USD Inspect Capital Expenditure Open source
2015 2015-01-01 – 2015-12-31	89650000	174084000 Derived	-84434000	Unavailable	Unavailable	-75583000 Derived	Source 2015-01-01 – 2015-12-31: 89650000 USD Inspect Revenue Open source 2015-01-01 – 2015-12-31: -84434000 USD Inspect Operating Income Open source 2015-01-01 – 2015-12-31: -71515000 USD Inspect Operating Cash Flow Open source 2015-01-01 – 2015-12-31: 4068000 USD Inspect Capital Expenditure Open source
2016 2016-01-01 – 2016-12-31	109619000	184346000 Derived	-74727000	Unavailable	Unavailable	3380000 Derived	Source 2016-01-01 – 2016-12-31: 109619000 USD Inspect Revenue Open source 2016-01-01 – 2016-12-31: -74727000 USD Inspect Operating Income Open source 2016-01-01 – 2016-12-31: 8989000 USD Inspect Operating Cash Flow Open source 2016-01-01 – 2016-12-31: 5609000 USD Inspect Capital Expenditure Open source
2017 2017-01-01 – 2017-12-31	138882000	231433000 Derived	-92551000	Unavailable	Unavailable	-46212000 Derived	Source 2017-01-01 – 2017-12-31: 138882000 USD Inspect Revenue Open source 2017-01-01 – 2017-12-31: -92551000 USD Inspect Operating Income Open source 2017-01-01 – 2017-12-31: -29085000 USD Inspect Operating Cash Flow Open source 2017-01-01 – 2017-12-31: 17127000 USD Inspect Capital Expenditure Open source
2018 2018-01-01 – 2018-12-31	75589000	256916000 Derived	-181327000	Unavailable	Unavailable	-164609000 Derived	Source 2018-01-01 – 2018-12-31: 75589000 USD Inspect Revenue Open source 2018-01-01 – 2018-12-31: -181327000 USD Inspect Operating Income Open source 2018-01-01 – 2018-12-31: -155590000 USD Inspect Operating Cash Flow Open source 2018-01-01 – 2018-12-31: 9019000 USD Inspect Capital Expenditure Open source
2019 2019-01-01 – 2019-12-31	23868000	321959000 Derived	-298091000	Unavailable	Unavailable	-206578000 Derived	Source 2019-01-01 – 2019-12-31: 23868000 USD Inspect Revenue Open source 2019-01-01 – 2019-12-31: -298091000 USD Inspect Operating Income Open source 2019-01-01 – 2019-12-31: -204802000 USD Inspect Operating Cash Flow Open source 2019-01-01 – 2019-12-31: 1776000 USD Inspect Capital Expenditure Open source

Amounts are exact, in USD.

Growth

Sales over time and how quickly they are changing.

Revenue

Revenue reported for each complete financial period.

USD 23.9M 2019

Values and sources

Revenue values and source evidence
Period	Series	Value(USD)	Source evidence
20102010-12-31	Revenue	116772000	Revenue: 116772000 Open source
20112011-12-31	Revenue	283068000	Revenue: 283068000 Open source
20122012-12-31	Revenue	63921000	Revenue: 63921000 Open source
20132013-12-31	Revenue	35465000	Revenue: 35465000 Open source
20142014-12-31	Revenue	52250000	Revenue: 52250000 Open source
20152015-12-31	Revenue	89650000	Revenue: 89650000 Open source
20162016-12-31	Revenue	109619000	Revenue: 109619000 Open source
20172017-12-31	Revenue	138882000	Revenue: 138882000 Open source
20182018-12-31	Revenue	75589000	Revenue: 75589000 Open source
20192019-12-31	Revenue	23868000	Revenue: 23868000 Open source

Revenue growth

Change in revenue from the same financial period one year earlier.

-68.4% 2019

Values and sources

Revenue growth values and source evidence
Period	Series	Value	Source evidence
20102010-12-31	Year over year	476.7%	Revenue: 116772000 Open source Revenue: 20249000 Open source
20112011-12-31	Year over year	142.4%	Revenue: 283068000 Open source Revenue: 116772000 Open source
20122012-12-31	Year over year	-77.4%	Revenue: 63921000 Open source Revenue: 283068000 Open source
20132013-12-31	Year over year	-44.5%	Revenue: 35465000 Open source Revenue: 63921000 Open source
20142014-12-31	Year over year	47.3%	Revenue: 52250000 Open source Revenue: 35465000 Open source
20152015-12-31	Year over year	71.6%	Revenue: 89650000 Open source Revenue: 52250000 Open source
20162016-12-31	Year over year	22.3%	Revenue: 109619000 Open source Revenue: 89650000 Open source
20172017-12-31	Year over year	26.7%	Revenue: 138882000 Open source Revenue: 109619000 Open source
20182018-12-31	Year over year	-45.6%	Revenue: 75589000 Open source Revenue: 138882000 Open source
20192019-12-31	Year over year	-68.4%	Revenue: 23868000 Open source Revenue: 75589000 Open source

Profit and cash

How much revenue becomes profit, and how much cash operations generate.

Profit margins

Operating income, net income and free cash flow as a share of revenue.

Operating margin -1,248.9% 2019

Net margin 31.9% 2010

Free cash flow margin -865.5% 2019

Operating margin
Net margin
Free cash flow margin

Values and sources

Profit margins values and source evidence
Period	Series	Value	Source evidence
20102010-12-31	Operating margin	31.2%	Operating Income: 36465000 Open source Revenue: 116772000 Open source
20112011-12-31	Operating margin	63.5%	Operating Income: 179701000 Open source Revenue: 283068000 Open source
20122012-12-31	Operating margin	-94%	Operating Income: -60106000 Open source Revenue: 63921000 Open source
20132013-12-31	Operating margin	-309%	Operating Income: -109591000 Open source Revenue: 35465000 Open source
20142014-12-31	Operating margin	-190.2%	Operating Income: -99396000 Open source Revenue: 52250000 Open source
20152015-12-31	Operating margin	-94.2%	Operating Income: -84434000 Open source Revenue: 89650000 Open source
20162016-12-31	Operating margin	-68.2%	Operating Income: -74727000 Open source Revenue: 109619000 Open source
20172017-12-31	Operating margin	-66.6%	Operating Income: -92551000 Open source Revenue: 138882000 Open source
20182018-12-31	Operating margin	-239.9%	Operating Income: -181327000 Open source Revenue: 75589000 Open source
20192019-12-31	Operating margin	-1,248.9%	Operating Income: -298091000 Open source Revenue: 23868000 Open source
20102010-12-31	Net margin	31.9%	Net Income: 37290000 Open source Revenue: 116772000 Open source
2011-12-31	Net margin	Not reported	Revenue: 283068000 Open source
2012-12-31	Net margin	Not reported	Revenue: 63921000 Open source
2013-12-31	Net margin	Not reported	Revenue: 35465000 Open source
2014-12-31	Net margin	Not reported	Revenue: 52250000 Open source
2015-12-31	Net margin	Not reported	Revenue: 89650000 Open source
2016-12-31	Net margin	Not reported	Revenue: 109619000 Open source
2017-12-31	Net margin	Not reported	Revenue: 138882000 Open source
2018-12-31	Net margin	Not reported	Revenue: 75589000 Open source
2019-12-31	Net margin	Not reported	Revenue: 23868000 Open source
20102010-12-31	Free cash flow margin	-2.3%	Revenue: 116772000 Open source Operating Cash Flow: -1057000 Open source Capital Expenditure: 1671000 Open source
20112011-12-31	Free cash flow margin	72.4%	Revenue: 283068000 Open source Operating Cash Flow: 213725000 Open source Capital Expenditure: 8699000 Open source
20122012-12-31	Free cash flow margin	-10.2%	Revenue: 63921000 Open source Operating Cash Flow: 8999000 Open source Capital Expenditure: 15491000 Open source
20132013-12-31	Free cash flow margin	-271.5%	Revenue: 35465000 Open source Operating Cash Flow: -86832000 Open source Capital Expenditure: 9450000 Open source
20142014-12-31	Free cash flow margin	-140.7%	Revenue: 52250000 Open source Operating Cash Flow: -65168000 Open source Capital Expenditure: 8360000 Open source
20152015-12-31	Free cash flow margin	-84.3%	Revenue: 89650000 Open source Operating Cash Flow: -71515000 Open source Capital Expenditure: 4068000 Open source
20162016-12-31	Free cash flow margin	3.1%	Revenue: 109619000 Open source Operating Cash Flow: 8989000 Open source Capital Expenditure: 5609000 Open source
20172017-12-31	Free cash flow margin	-33.3%	Revenue: 138882000 Open source Operating Cash Flow: -29085000 Open source Capital Expenditure: 17127000 Open source
20182018-12-31	Free cash flow margin	-217.8%	Revenue: 75589000 Open source Operating Cash Flow: -155590000 Open source Capital Expenditure: 9019000 Open source
20192019-12-31	Free cash flow margin	-865.5%	Revenue: 23868000 Open source Operating Cash Flow: -204802000 Open source Capital Expenditure: 1776000 Open source

Operating cash flow

Cash generated by the company’s normal business operations.

USD -204.8M 2019

Values and sources

Operating cash flow values and source evidence
Period	Series	Value(USD)	Source evidence
20102010-12-31	Operating cash flow	-1057000	Operating Cash Flow: -1057000 Open source
20112011-12-31	Operating cash flow	213725000	Operating Cash Flow: 213725000 Open source
20122012-12-31	Operating cash flow	8999000	Operating Cash Flow: 8999000 Open source
20132013-12-31	Operating cash flow	-86832000	Operating Cash Flow: -86832000 Open source
20142014-12-31	Operating cash flow	-65168000	Operating Cash Flow: -65168000 Open source
20152015-12-31	Operating cash flow	-71515000	Operating Cash Flow: -71515000 Open source
20162016-12-31	Operating cash flow	8989000	Operating Cash Flow: 8989000 Open source
20172017-12-31	Operating cash flow	-29085000	Operating Cash Flow: -29085000 Open source
20182018-12-31	Operating cash flow	-155590000	Operating Cash Flow: -155590000 Open source
20192019-12-31	Operating cash flow	-204802000	Operating Cash Flow: -204802000 Open source

Free cash flow

Operating cash flow minus capital expenditure for the same period and unit.

USD -206.6M 2019

Values and sources

Free cash flow values and source evidence
Period	Series	Value(USD)	Source evidence
20102010-12-31	Free cash flow	-2728000	Operating Cash Flow: -1057000 Open source Capital Expenditure: 1671000 Open source
20112011-12-31	Free cash flow	205026000	Operating Cash Flow: 213725000 Open source Capital Expenditure: 8699000 Open source
20122012-12-31	Free cash flow	-6492000	Operating Cash Flow: 8999000 Open source Capital Expenditure: 15491000 Open source
20132013-12-31	Free cash flow	-96282000	Operating Cash Flow: -86832000 Open source Capital Expenditure: 9450000 Open source
20142014-12-31	Free cash flow	-73528000	Operating Cash Flow: -65168000 Open source Capital Expenditure: 8360000 Open source
20152015-12-31	Free cash flow	-75583000	Operating Cash Flow: -71515000 Open source Capital Expenditure: 4068000 Open source
20162016-12-31	Free cash flow	3380000	Operating Cash Flow: 8989000 Open source Capital Expenditure: 5609000 Open source
20172017-12-31	Free cash flow	-46212000	Operating Cash Flow: -29085000 Open source Capital Expenditure: 17127000 Open source
20182018-12-31	Free cash flow	-164609000	Operating Cash Flow: -155590000 Open source Capital Expenditure: 9019000 Open source
20192019-12-31	Free cash flow	-206578000	Operating Cash Flow: -204802000 Open source Capital Expenditure: 1776000 Open source

Balance sheet

Liabilities and short-term ability to meet obligations at each period end.

Liabilities to assets

Total liabilities as a share of total assets.

26.5% 2019

Values and sources

Liabilities to assets values and source evidence
Period	Series	Value	Source evidence
20102010-12-31	Liabilities / assets	9.4%	Total Liabilities: 21466000 Open source Total Assets: 227569000 Open source
20112011-12-31	Liabilities / assets	4.2%	Total Liabilities: 17831000 Open source Total Assets: 420909000 Open source
20122012-12-31	Liabilities / assets	11.3%	Total Liabilities: 46142000 Open source Total Assets: 406629000 Open source
20132013-12-31	Liabilities / assets	14.8%	Total Liabilities: 46978000 Open source Total Assets: 316815000 Open source
2014-12-31	Liabilities / assets	Not reported	No source recorded
20152015-12-31	Liabilities / assets	12.1%	Total Liabilities: 51064000 Open source Total Assets: 421040000 Open source
20162016-12-31	Liabilities / assets	22.2%	Total Liabilities: 105829000 Open source Total Assets: 477737000 Open source
20172017-12-31	Liabilities / assets	18.6%	Total Liabilities: 85277000 Open source Total Assets: 459431000 Open source
20182018-12-31	Liabilities / assets	13.3%	Total Liabilities: 70555000 Open source Total Assets: 531563000 Open source
20192019-12-31	Liabilities / assets	26.5%	Total Liabilities: 163905000 Open source Total Assets: 618365000 Open source

Current assets to current liabilities

Current assets divided by current liabilities.

5.08× 2019

Values and sources

Current assets to current liabilities values and source evidence
Period	Series	Value	Source evidence
20102010-12-31	Current assets / current liabilities	12.14×	Current Assets: 214302000 Open source Current Liabilities: 17652000 Open source
20112011-12-31	Current assets / current liabilities	24.92×	Current Assets: 399421000 Open source Current Liabilities: 16028000 Open source
20122012-12-31	Current assets / current liabilities	19.67×	Current Assets: 357167000 Open source Current Liabilities: 18161000 Open source
20132013-12-31	Current assets / current liabilities	12.1×	Current Assets: 265591000 Open source Current Liabilities: 21942000 Open source
2014-12-31	Current assets / current liabilities	Not reported	No source recorded
20152015-12-31	Current assets / current liabilities	9.66×	Current Assets: 374708000 Open source Current Liabilities: 38782000 Open source
20162016-12-31	Current assets / current liabilities	6.06×	Current Assets: 428000000 Open source Current Liabilities: 70676000 Open source
20172017-12-31	Current assets / current liabilities	8.25×	Current Assets: 366926000 Open source Current Liabilities: 44487000 Open source
20182018-12-31	Current assets / current liabilities	8.57×	Current Assets: 441423000 Open source Current Liabilities: 51511000 Open source
20192019-12-31	Current assets / current liabilities	5.08×	Current Assets: 539127000 Open source Current Liabilities: 106104000 Open source

Cash generation

Compare reported profit with operating cash and capital spending. Free cash flow is calculated as operating cash flow minus capital expenditure when both exact, consolidated amounts match the same period and unit.

Cash generation by annual reporting period
Period	Net income	Operating cash flow	Capital expenditure	Free cash flow
2010 2010-01-01 – 2010-12-31	USD 37.29 million Exact value Exact value: 37290000 USD 2010-01-01 – 2010-12-31: 37290000 USD Inspect Net Income Open source Share or cite Citation for Net Income · Momenta Pharmaceuticals, Inc. · 2010-12-31 Momenta Pharmaceuticals, Inc. (edgar:1235010) Net Income: 37290000 USD Concept: fundies:NetIncome Period: 2010-01-01 to 2010-12-31 Values: Latest reported Published: 2026-11-02T09:32:59Z Snapshot: 2e167c544acd282b1ed83fd55a50ba564bc60fa7bc814e8250bdebe50baf9663 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1235010/explain?concept=fundies%3ANetIncome&period=2010-12-31&surface=latest&period_type=duration&start=2010-01-01&unit=USD&dimensions= Input fundies:NetIncome: 37290000 USD (2010-01-01 to 2010-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1235010/0001047469-11-001964.txt#8489 The citation records this snapshot. The page link may show a newer release later.	−USD 1.06 million Exact value Exact value: -1057000 USD 2010-01-01 – 2010-12-31: -1057000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Momenta Pharmaceuticals, Inc. · 2010-12-31 Momenta Pharmaceuticals, Inc. (edgar:1235010) Operating Cash Flow: -1057000 USD Concept: fundies:OperatingCashFlow Period: 2010-01-01 to 2010-12-31 Values: Latest reported Published: 2026-11-02T09:32:59Z Snapshot: 2e167c544acd282b1ed83fd55a50ba564bc60fa7bc814e8250bdebe50baf9663 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1235010/explain?concept=fundies%3AOperatingCashFlow&period=2010-12-31&surface=latest&period_type=duration&start=2010-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -1057000 USD (2010-01-01 to 2010-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1235010/000104746913001950/mnta-20121231.xml#458504 Filing: 000104746913001950 The citation records this snapshot. The page link may show a newer release later.	USD 1.67 million Exact value Exact value: 1671000 USD 2010-01-01 – 2010-12-31: 1671000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Momenta Pharmaceuticals, Inc. · 2010-12-31 Momenta Pharmaceuticals, Inc. (edgar:1235010) Capital Expenditure: 1671000 USD Concept: fundies:CapitalExpenditure Period: 2010-01-01 to 2010-12-31 Values: Latest reported Published: 2026-11-02T09:32:59Z Snapshot: 2e167c544acd282b1ed83fd55a50ba564bc60fa7bc814e8250bdebe50baf9663 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1235010/explain?concept=fundies%3ACapitalExpenditure&period=2010-12-31&surface=latest&period_type=duration&start=2010-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 1671000 USD (2010-01-01 to 2010-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1235010/000104746913001950/mnta-20121231.xml#458897 Filing: 000104746913001950 The citation records this snapshot. The page link may show a newer release later.	−USD 2.73 million Calculation and evidence -1057000 − 1671000 USD Exact free cash flow: -2728000 USD 2010-01-01 – 2010-12-31: -1057000 USD · Inspect Operating Cash Flow · Source 2010-01-01 – 2010-12-31: 1671000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Momenta Pharmaceuticals, Inc. · 2010-12-31 Momenta Pharmaceuticals, Inc. (edgar:1235010) Free cash flow: -2728000 USD Concept: free-cash-flow Period: 2010-01-01 to 2010-12-31 Values: Latest reported Published: 2026-11-02T09:32:59Z Snapshot: 2e167c544acd282b1ed83fd55a50ba564bc60fa7bc814e8250bdebe50baf9663 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1235010?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -1057000 USD (2010-01-01 to 2010-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1235010/000104746913001950/mnta-20121231.xml#458504 Filing: 000104746913001950 Input fundies:CapitalExpenditure: 1671000 USD (2010-01-01 to 2010-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1235010/000104746913001950/mnta-20121231.xml#458897 Filing: 000104746913001950 The citation records this snapshot. The page link may show a newer release later.
2011 2011-01-01 – 2011-12-31	Unavailable Not reported for this period.	USD 213.73 million Exact value Exact value: 213725000 USD 2011-01-01 – 2011-12-31: 213725000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Momenta Pharmaceuticals, Inc. · 2011-12-31 Momenta Pharmaceuticals, Inc. (edgar:1235010) Operating Cash Flow: 213725000 USD Concept: fundies:OperatingCashFlow Period: 2011-01-01 to 2011-12-31 Values: Latest reported Published: 2026-11-02T09:32:59Z Snapshot: 2e167c544acd282b1ed83fd55a50ba564bc60fa7bc814e8250bdebe50baf9663 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1235010/explain?concept=fundies%3AOperatingCashFlow&period=2011-12-31&surface=latest&period_type=duration&start=2011-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: 213725000 USD (2011-01-01 to 2011-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1235010/000104746914001572/mnta-20131231.xml#148051 Filing: 000104746914001572 The citation records this snapshot. The page link may show a newer release later.	USD 8.7 million Exact value Exact value: 8699000 USD 2011-01-01 – 2011-12-31: 8699000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Momenta Pharmaceuticals, Inc. · 2011-12-31 Momenta Pharmaceuticals, Inc. (edgar:1235010) Capital Expenditure: 8699000 USD Concept: fundies:CapitalExpenditure Period: 2011-01-01 to 2011-12-31 Values: Latest reported Published: 2026-11-02T09:32:59Z Snapshot: 2e167c544acd282b1ed83fd55a50ba564bc60fa7bc814e8250bdebe50baf9663 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1235010/explain?concept=fundies%3ACapitalExpenditure&period=2011-12-31&surface=latest&period_type=duration&start=2011-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 8699000 USD (2011-01-01 to 2011-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1235010/000104746914001572/mnta-20131231.xml#148931 Filing: 000104746914001572 The citation records this snapshot. The page link may show a newer release later.	USD 205.03 million Calculation and evidence 213725000 − 8699000 USD Exact free cash flow: 205026000 USD 2011-01-01 – 2011-12-31: 213725000 USD · Inspect Operating Cash Flow · Source 2011-01-01 – 2011-12-31: 8699000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Momenta Pharmaceuticals, Inc. · 2011-12-31 Momenta Pharmaceuticals, Inc. (edgar:1235010) Free cash flow: 205026000 USD Concept: free-cash-flow Period: 2011-01-01 to 2011-12-31 Values: Latest reported Published: 2026-11-02T09:32:59Z Snapshot: 2e167c544acd282b1ed83fd55a50ba564bc60fa7bc814e8250bdebe50baf9663 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1235010?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: 213725000 USD (2011-01-01 to 2011-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1235010/000104746914001572/mnta-20131231.xml#148051 Filing: 000104746914001572 Input fundies:CapitalExpenditure: 8699000 USD (2011-01-01 to 2011-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1235010/000104746914001572/mnta-20131231.xml#148931 Filing: 000104746914001572 The citation records this snapshot. The page link may show a newer release later.
2012 2012-01-01 – 2012-12-31	Unavailable Not reported for this period.	USD 9 million Exact value Exact value: 8999000 USD 2012-01-01 – 2012-12-31: 8999000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Momenta Pharmaceuticals, Inc. · 2012-12-31 Momenta Pharmaceuticals, Inc. (edgar:1235010) Operating Cash Flow: 8999000 USD Concept: fundies:OperatingCashFlow Period: 2012-01-01 to 2012-12-31 Values: Latest reported Published: 2026-11-02T09:32:59Z Snapshot: 2e167c544acd282b1ed83fd55a50ba564bc60fa7bc814e8250bdebe50baf9663 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1235010/explain?concept=fundies%3AOperatingCashFlow&period=2012-12-31&surface=latest&period_type=duration&start=2012-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: 8999000 USD (2012-01-01 to 2012-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1235010/000104746914001572/mnta-20131231.xml#147837 Filing: 000104746914001572 The citation records this snapshot. The page link may show a newer release later.	USD 15.49 million Exact value Exact value: 15491000 USD 2012-01-01 – 2012-12-31: 15491000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Momenta Pharmaceuticals, Inc. · 2012-12-31 Momenta Pharmaceuticals, Inc. (edgar:1235010) Capital Expenditure: 15491000 USD Concept: fundies:CapitalExpenditure Period: 2012-01-01 to 2012-12-31 Values: Latest reported Published: 2026-11-02T09:32:59Z Snapshot: 2e167c544acd282b1ed83fd55a50ba564bc60fa7bc814e8250bdebe50baf9663 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1235010/explain?concept=fundies%3ACapitalExpenditure&period=2012-12-31&surface=latest&period_type=duration&start=2012-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 15491000 USD (2012-01-01 to 2012-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1235010/000104746914001572/mnta-20131231.xml#148756 Filing: 000104746914001572 The citation records this snapshot. The page link may show a newer release later.	−USD 6.49 million Calculation and evidence 8999000 − 15491000 USD Exact free cash flow: -6492000 USD 2012-01-01 – 2012-12-31: 8999000 USD · Inspect Operating Cash Flow · Source 2012-01-01 – 2012-12-31: 15491000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Momenta Pharmaceuticals, Inc. · 2012-12-31 Momenta Pharmaceuticals, Inc. (edgar:1235010) Free cash flow: -6492000 USD Concept: free-cash-flow Period: 2012-01-01 to 2012-12-31 Values: Latest reported Published: 2026-11-02T09:32:59Z Snapshot: 2e167c544acd282b1ed83fd55a50ba564bc60fa7bc814e8250bdebe50baf9663 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1235010?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: 8999000 USD (2012-01-01 to 2012-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1235010/000104746914001572/mnta-20131231.xml#147837 Filing: 000104746914001572 Input fundies:CapitalExpenditure: 15491000 USD (2012-01-01 to 2012-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1235010/000104746914001572/mnta-20131231.xml#148756 Filing: 000104746914001572 The citation records this snapshot. The page link may show a newer release later.
2013 2013-01-01 – 2013-12-31	Unavailable Not reported for this period.	−USD 86.83 million Exact value Exact value: -86832000 USD 2013-01-01 – 2013-12-31: -86832000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Momenta Pharmaceuticals, Inc. · 2013-12-31 Momenta Pharmaceuticals, Inc. (edgar:1235010) Operating Cash Flow: -86832000 USD Concept: fundies:OperatingCashFlow Period: 2013-01-01 to 2013-12-31 Values: Latest reported Published: 2026-11-02T09:32:59Z Snapshot: 2e167c544acd282b1ed83fd55a50ba564bc60fa7bc814e8250bdebe50baf9663 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1235010/explain?concept=fundies%3AOperatingCashFlow&period=2013-12-31&surface=latest&period_type=duration&start=2013-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -86832000 USD (2013-01-01 to 2013-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1235010/000104746914001572/mnta-20131231.xml#152293 Filing: 000104746914001572 The citation records this snapshot. The page link may show a newer release later.	USD 9.45 million Exact value Exact value: 9450000 USD 2013-01-01 – 2013-12-31: 9450000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Momenta Pharmaceuticals, Inc. · 2013-12-31 Momenta Pharmaceuticals, Inc. (edgar:1235010) Capital Expenditure: 9450000 USD Concept: fundies:CapitalExpenditure Period: 2013-01-01 to 2013-12-31 Values: Latest reported Published: 2026-11-02T09:32:59Z Snapshot: 2e167c544acd282b1ed83fd55a50ba564bc60fa7bc814e8250bdebe50baf9663 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1235010/explain?concept=fundies%3ACapitalExpenditure&period=2013-12-31&surface=latest&period_type=duration&start=2013-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 9450000 USD (2013-01-01 to 2013-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1235010/000104746914001572/mnta-20131231.xml#1451436 Filing: 000104746914001572 The citation records this snapshot. The page link may show a newer release later.	−USD 96.28 million Calculation and evidence -86832000 − 9450000 USD Exact free cash flow: -96282000 USD 2013-01-01 – 2013-12-31: -86832000 USD · Inspect Operating Cash Flow · Source 2013-01-01 – 2013-12-31: 9450000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Momenta Pharmaceuticals, Inc. · 2013-12-31 Momenta Pharmaceuticals, Inc. (edgar:1235010) Free cash flow: -96282000 USD Concept: free-cash-flow Period: 2013-01-01 to 2013-12-31 Values: Latest reported Published: 2026-11-02T09:32:59Z Snapshot: 2e167c544acd282b1ed83fd55a50ba564bc60fa7bc814e8250bdebe50baf9663 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1235010?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -86832000 USD (2013-01-01 to 2013-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1235010/000104746914001572/mnta-20131231.xml#152293 Filing: 000104746914001572 Input fundies:CapitalExpenditure: 9450000 USD (2013-01-01 to 2013-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1235010/000104746914001572/mnta-20131231.xml#1451436 Filing: 000104746914001572 The citation records this snapshot. The page link may show a newer release later.
2014 2014-01-01 – 2014-12-31	Unavailable Not reported for this period.	−USD 65.17 million Exact value Exact value: -65168000 USD 2014-01-01 – 2014-12-31: -65168000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Momenta Pharmaceuticals, Inc. · 2014-12-31 Momenta Pharmaceuticals, Inc. (edgar:1235010) Operating Cash Flow: -65168000 USD Concept: fundies:OperatingCashFlow Period: 2014-01-01 to 2014-12-31 Values: Latest reported Published: 2026-11-02T09:32:59Z Snapshot: 2e167c544acd282b1ed83fd55a50ba564bc60fa7bc814e8250bdebe50baf9663 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1235010/explain?concept=fundies%3AOperatingCashFlow&period=2014-12-31&surface=latest&period_type=duration&start=2014-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -65168000 USD (2014-01-01 to 2014-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1235010/000123501017000003/mnta-20161231.xml#301386 Filing: 000123501017000003 The citation records this snapshot. The page link may show a newer release later.	USD 8.36 million Exact value Exact value: 8360000 USD 2014-01-01 – 2014-12-31: 8360000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Momenta Pharmaceuticals, Inc. · 2014-12-31 Momenta Pharmaceuticals, Inc. (edgar:1235010) Capital Expenditure: 8360000 USD Concept: fundies:CapitalExpenditure Period: 2014-01-01 to 2014-12-31 Values: Latest reported Published: 2026-11-02T09:32:59Z Snapshot: 2e167c544acd282b1ed83fd55a50ba564bc60fa7bc814e8250bdebe50baf9663 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1235010/explain?concept=fundies%3ACapitalExpenditure&period=2014-12-31&surface=latest&period_type=duration&start=2014-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 8360000 USD (2014-01-01 to 2014-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1235010/000123501017000003/mnta-20161231.xml#318514 Filing: 000123501017000003 The citation records this snapshot. The page link may show a newer release later.	−USD 73.53 million Calculation and evidence -65168000 − 8360000 USD Exact free cash flow: -73528000 USD 2014-01-01 – 2014-12-31: -65168000 USD · Inspect Operating Cash Flow · Source 2014-01-01 – 2014-12-31: 8360000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Momenta Pharmaceuticals, Inc. · 2014-12-31 Momenta Pharmaceuticals, Inc. (edgar:1235010) Free cash flow: -73528000 USD Concept: free-cash-flow Period: 2014-01-01 to 2014-12-31 Values: Latest reported Published: 2026-11-02T09:32:59Z Snapshot: 2e167c544acd282b1ed83fd55a50ba564bc60fa7bc814e8250bdebe50baf9663 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1235010?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -65168000 USD (2014-01-01 to 2014-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1235010/000123501017000003/mnta-20161231.xml#301386 Filing: 000123501017000003 Input fundies:CapitalExpenditure: 8360000 USD (2014-01-01 to 2014-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1235010/000123501017000003/mnta-20161231.xml#318514 Filing: 000123501017000003 The citation records this snapshot. The page link may show a newer release later.
2015 2015-01-01 – 2015-12-31	Unavailable Not reported for this period.	−USD 71.52 million Exact value Exact value: -71515000 USD 2015-01-01 – 2015-12-31: -71515000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Momenta Pharmaceuticals, Inc. · 2015-12-31 Momenta Pharmaceuticals, Inc. (edgar:1235010) Operating Cash Flow: -71515000 USD Concept: fundies:OperatingCashFlow Period: 2015-01-01 to 2015-12-31 Values: Latest reported Published: 2026-11-02T09:32:59Z Snapshot: 2e167c544acd282b1ed83fd55a50ba564bc60fa7bc814e8250bdebe50baf9663 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1235010/explain?concept=fundies%3AOperatingCashFlow&period=2015-12-31&surface=latest&period_type=duration&start=2015-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -71515000 USD (2015-01-01 to 2015-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1235010/000123501018000004/mnta-20171231.xml#345226 Filing: 000123501018000004 The citation records this snapshot. The page link may show a newer release later.	USD 4.07 million Exact value Exact value: 4068000 USD 2015-01-01 – 2015-12-31: 4068000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Momenta Pharmaceuticals, Inc. · 2015-12-31 Momenta Pharmaceuticals, Inc. (edgar:1235010) Capital Expenditure: 4068000 USD Concept: fundies:CapitalExpenditure Period: 2015-01-01 to 2015-12-31 Values: Latest reported Published: 2026-11-02T09:32:59Z Snapshot: 2e167c544acd282b1ed83fd55a50ba564bc60fa7bc814e8250bdebe50baf9663 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1235010/explain?concept=fundies%3ACapitalExpenditure&period=2015-12-31&surface=latest&period_type=duration&start=2015-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 4068000 USD (2015-01-01 to 2015-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1235010/000123501018000004/mnta-20171231.xml#362486 Filing: 000123501018000004 The citation records this snapshot. The page link may show a newer release later.	−USD 75.58 million Calculation and evidence -71515000 − 4068000 USD Exact free cash flow: -75583000 USD 2015-01-01 – 2015-12-31: -71515000 USD · Inspect Operating Cash Flow · Source 2015-01-01 – 2015-12-31: 4068000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Momenta Pharmaceuticals, Inc. · 2015-12-31 Momenta Pharmaceuticals, Inc. (edgar:1235010) Free cash flow: -75583000 USD Concept: free-cash-flow Period: 2015-01-01 to 2015-12-31 Values: Latest reported Published: 2026-11-02T09:32:59Z Snapshot: 2e167c544acd282b1ed83fd55a50ba564bc60fa7bc814e8250bdebe50baf9663 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1235010?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -71515000 USD (2015-01-01 to 2015-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1235010/000123501018000004/mnta-20171231.xml#345226 Filing: 000123501018000004 Input fundies:CapitalExpenditure: 4068000 USD (2015-01-01 to 2015-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1235010/000123501018000004/mnta-20171231.xml#362486 Filing: 000123501018000004 The citation records this snapshot. The page link may show a newer release later.
2016 2016-01-01 – 2016-12-31	Unavailable Not reported for this period.	USD 8.99 million Exact value Exact value: 8989000 USD 2016-01-01 – 2016-12-31: 8989000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Momenta Pharmaceuticals, Inc. · 2016-12-31 Momenta Pharmaceuticals, Inc. (edgar:1235010) Operating Cash Flow: 8989000 USD Concept: fundies:OperatingCashFlow Period: 2016-01-01 to 2016-12-31 Values: Latest reported Published: 2026-11-02T09:32:59Z Snapshot: 2e167c544acd282b1ed83fd55a50ba564bc60fa7bc814e8250bdebe50baf9663 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1235010/explain?concept=fundies%3AOperatingCashFlow&period=2016-12-31&surface=latest&period_type=duration&start=2016-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: 8989000 USD (2016-01-01 to 2016-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1235010/000123501019000002/mnta-20181231.xml#430732 Filing: 000123501019000002 The citation records this snapshot. The page link may show a newer release later.	USD 5.61 million Exact value Exact value: 5609000 USD 2016-01-01 – 2016-12-31: 5609000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Momenta Pharmaceuticals, Inc. · 2016-12-31 Momenta Pharmaceuticals, Inc. (edgar:1235010) Capital Expenditure: 5609000 USD Concept: fundies:CapitalExpenditure Period: 2016-01-01 to 2016-12-31 Values: Latest reported Published: 2026-11-02T09:32:59Z Snapshot: 2e167c544acd282b1ed83fd55a50ba564bc60fa7bc814e8250bdebe50baf9663 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1235010/explain?concept=fundies%3ACapitalExpenditure&period=2016-12-31&surface=latest&period_type=duration&start=2016-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 5609000 USD (2016-01-01 to 2016-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1235010/000123501019000002/mnta-20181231.xml#452124 Filing: 000123501019000002 The citation records this snapshot. The page link may show a newer release later.	USD 3.38 million Calculation and evidence 8989000 − 5609000 USD Exact free cash flow: 3380000 USD 2016-01-01 – 2016-12-31: 8989000 USD · Inspect Operating Cash Flow · Source 2016-01-01 – 2016-12-31: 5609000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Momenta Pharmaceuticals, Inc. · 2016-12-31 Momenta Pharmaceuticals, Inc. (edgar:1235010) Free cash flow: 3380000 USD Concept: free-cash-flow Period: 2016-01-01 to 2016-12-31 Values: Latest reported Published: 2026-11-02T09:32:59Z Snapshot: 2e167c544acd282b1ed83fd55a50ba564bc60fa7bc814e8250bdebe50baf9663 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1235010?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: 8989000 USD (2016-01-01 to 2016-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1235010/000123501019000002/mnta-20181231.xml#430732 Filing: 000123501019000002 Input fundies:CapitalExpenditure: 5609000 USD (2016-01-01 to 2016-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1235010/000123501019000002/mnta-20181231.xml#452124 Filing: 000123501019000002 The citation records this snapshot. The page link may show a newer release later.
2017 2017-01-01 – 2017-12-31	Unavailable Not reported for this period.	−USD 29.09 million Exact value Exact value: -29085000 USD 2017-01-01 – 2017-12-31: -29085000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Momenta Pharmaceuticals, Inc. · 2017-12-31 Momenta Pharmaceuticals, Inc. (edgar:1235010) Operating Cash Flow: -29085000 USD Concept: fundies:OperatingCashFlow Period: 2017-01-01 to 2017-12-31 Values: Latest reported Published: 2026-11-02T09:32:59Z Snapshot: 2e167c544acd282b1ed83fd55a50ba564bc60fa7bc814e8250bdebe50baf9663 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1235010/explain?concept=fundies%3AOperatingCashFlow&period=2017-12-31&surface=latest&period_type=duration&start=2017-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -29085000 USD (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1235010/000123501020000003/mnta1231201910k.htm#1498265 Filing: 000123501020000003 The citation records this snapshot. The page link may show a newer release later.	USD 17.13 million Exact value Exact value: 17127000 USD 2017-01-01 – 2017-12-31: 17127000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Momenta Pharmaceuticals, Inc. · 2017-12-31 Momenta Pharmaceuticals, Inc. (edgar:1235010) Capital Expenditure: 17127000 USD Concept: fundies:CapitalExpenditure Period: 2017-01-01 to 2017-12-31 Values: Latest reported Published: 2026-11-02T09:32:59Z Snapshot: 2e167c544acd282b1ed83fd55a50ba564bc60fa7bc814e8250bdebe50baf9663 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1235010/explain?concept=fundies%3ACapitalExpenditure&period=2017-12-31&surface=latest&period_type=duration&start=2017-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 17127000 USD (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1235010/000123501020000003/mnta1231201910k.htm#1504131 Filing: 000123501020000003 The citation records this snapshot. The page link may show a newer release later.	−USD 46.21 million Calculation and evidence -29085000 − 17127000 USD Exact free cash flow: -46212000 USD 2017-01-01 – 2017-12-31: -29085000 USD · Inspect Operating Cash Flow · Source 2017-01-01 – 2017-12-31: 17127000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Momenta Pharmaceuticals, Inc. · 2017-12-31 Momenta Pharmaceuticals, Inc. (edgar:1235010) Free cash flow: -46212000 USD Concept: free-cash-flow Period: 2017-01-01 to 2017-12-31 Values: Latest reported Published: 2026-11-02T09:32:59Z Snapshot: 2e167c544acd282b1ed83fd55a50ba564bc60fa7bc814e8250bdebe50baf9663 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1235010?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -29085000 USD (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1235010/000123501020000003/mnta1231201910k.htm#1498265 Filing: 000123501020000003 Input fundies:CapitalExpenditure: 17127000 USD (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1235010/000123501020000003/mnta1231201910k.htm#1504131 Filing: 000123501020000003 The citation records this snapshot. The page link may show a newer release later.
2018 2018-01-01 – 2018-12-31	Unavailable Not reported for this period.	−USD 155.59 million Exact value Exact value: -155590000 USD 2018-01-01 – 2018-12-31: -155590000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Momenta Pharmaceuticals, Inc. · 2018-12-31 Momenta Pharmaceuticals, Inc. (edgar:1235010) Operating Cash Flow: -155590000 USD Concept: fundies:OperatingCashFlow Period: 2018-01-01 to 2018-12-31 Values: Latest reported Published: 2026-11-02T09:32:59Z Snapshot: 2e167c544acd282b1ed83fd55a50ba564bc60fa7bc814e8250bdebe50baf9663 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1235010/explain?concept=fundies%3AOperatingCashFlow&period=2018-12-31&surface=latest&period_type=duration&start=2018-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -155590000 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1235010/000123501020000003/mnta1231201910k.htm#1497161 Filing: 000123501020000003 The citation records this snapshot. The page link may show a newer release later.	USD 9.02 million Exact value Exact value: 9019000 USD 2018-01-01 – 2018-12-31: 9019000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Momenta Pharmaceuticals, Inc. · 2018-12-31 Momenta Pharmaceuticals, Inc. (edgar:1235010) Capital Expenditure: 9019000 USD Concept: fundies:CapitalExpenditure Period: 2018-01-01 to 2018-12-31 Values: Latest reported Published: 2026-11-02T09:32:59Z Snapshot: 2e167c544acd282b1ed83fd55a50ba564bc60fa7bc814e8250bdebe50baf9663 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1235010/explain?concept=fundies%3ACapitalExpenditure&period=2018-12-31&surface=latest&period_type=duration&start=2018-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 9019000 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1235010/000123501020000003/mnta1231201910k.htm#1503235 Filing: 000123501020000003 The citation records this snapshot. The page link may show a newer release later.	−USD 164.61 million Calculation and evidence -155590000 − 9019000 USD Exact free cash flow: -164609000 USD 2018-01-01 – 2018-12-31: -155590000 USD · Inspect Operating Cash Flow · Source 2018-01-01 – 2018-12-31: 9019000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Momenta Pharmaceuticals, Inc. · 2018-12-31 Momenta Pharmaceuticals, Inc. (edgar:1235010) Free cash flow: -164609000 USD Concept: free-cash-flow Period: 2018-01-01 to 2018-12-31 Values: Latest reported Published: 2026-11-02T09:32:59Z Snapshot: 2e167c544acd282b1ed83fd55a50ba564bc60fa7bc814e8250bdebe50baf9663 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1235010?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -155590000 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1235010/000123501020000003/mnta1231201910k.htm#1497161 Filing: 000123501020000003 Input fundies:CapitalExpenditure: 9019000 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1235010/000123501020000003/mnta1231201910k.htm#1503235 Filing: 000123501020000003 The citation records this snapshot. The page link may show a newer release later.
2019 2019-01-01 – 2019-12-31	Unavailable Not reported for this period.	−USD 204.8 million Exact value Exact value: -204802000 USD 2019-01-01 – 2019-12-31: -204802000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Momenta Pharmaceuticals, Inc. · 2019-12-31 Momenta Pharmaceuticals, Inc. (edgar:1235010) Operating Cash Flow: -204802000 USD Concept: fundies:OperatingCashFlow Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-02T09:32:59Z Snapshot: 2e167c544acd282b1ed83fd55a50ba564bc60fa7bc814e8250bdebe50baf9663 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1235010/explain?concept=fundies%3AOperatingCashFlow&period=2019-12-31&surface=latest&period_type=duration&start=2019-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -204802000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1235010/000123501020000003/mnta1231201910k.htm#1496086 Filing: 000123501020000003 The citation records this snapshot. The page link may show a newer release later.	USD 1.78 million Exact value Exact value: 1776000 USD 2019-01-01 – 2019-12-31: 1776000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Momenta Pharmaceuticals, Inc. · 2019-12-31 Momenta Pharmaceuticals, Inc. (edgar:1235010) Capital Expenditure: 1776000 USD Concept: fundies:CapitalExpenditure Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-02T09:32:59Z Snapshot: 2e167c544acd282b1ed83fd55a50ba564bc60fa7bc814e8250bdebe50baf9663 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1235010/explain?concept=fundies%3ACapitalExpenditure&period=2019-12-31&surface=latest&period_type=duration&start=2019-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 1776000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1235010/000123501020000003/mnta1231201910k.htm#1502339 Filing: 000123501020000003 The citation records this snapshot. The page link may show a newer release later.	−USD 206.58 million Calculation and evidence -204802000 − 1776000 USD Exact free cash flow: -206578000 USD 2019-01-01 – 2019-12-31: -204802000 USD · Inspect Operating Cash Flow · Source 2019-01-01 – 2019-12-31: 1776000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Momenta Pharmaceuticals, Inc. · 2019-12-31 Momenta Pharmaceuticals, Inc. (edgar:1235010) Free cash flow: -206578000 USD Concept: free-cash-flow Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-02T09:32:59Z Snapshot: 2e167c544acd282b1ed83fd55a50ba564bc60fa7bc814e8250bdebe50baf9663 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1235010?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -204802000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1235010/000123501020000003/mnta1231201910k.htm#1496086 Filing: 000123501020000003 Input fundies:CapitalExpenditure: 1776000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1235010/000123501020000003/mnta1231201910k.htm#1502339 Filing: 000123501020000003 The citation records this snapshot. The page link may show a newer release later.

Capital expenditure uses the canonical mapped positive-spending convention. A missing, ambiguous, incompatible, or negative-sign input is left blank. Values use the latest reported version.

Dataset coverage and company identifiers

Coverage reflects filings processed into this Fundies dataset; it does not imply every source filing is loaded.

180 filings · 2,695 latest values · 2,695 originally reported values

Dataset published 2026-11-02. Source filing dates and reporting periods are shown separately.

Identifiers: 0001235010, 1235010, MNTA, edgar:1235010

Also known as MOMENTA PHARMACEUTICALS INC, MOMENTA PHARMACEUTICALS, INC., Momenta Pharmaceuticals, Inc., Momenta Pharmaceuticals, Inc.

Momenta Pharmaceuticals, Inc.

Latest quarter

Revenue

Operating margin

Operating cash flow

Free cash flow

Reported share-count change

Trailing twelve months

Net income

Company performance

What changed year over year

Revenue

Operating cash flow

Capital expenditure

Where revenue goes

2019 2019-01-01 – 2019-12-31

Cash

Share of revenue by period

Growth

Profit and cash

Balance sheet

Cash generation